Related Experiment Video
Updated: Oct 7, 2025
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
656
Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working
Talia Baker1, Parissa Tabrizian2, Ivan Zendejas3
1University of Utah, Salt Lake City, UT, USA.
Summary
Transarterial radioembolization (TARE) using yttrium-90 (90Y) effectively converts borderline-resectable liver cancer patients into surgical candidates. This expert consensus provides recommendations for its safe and feasible application.
Area of Science:
- Hepatobiliary Surgery
- Interventional Radiology
- Oncology
Background:
- Transarterial radioembolization (TARE) with yttrium-90 (90Y) is a viable treatment for borderline-resectable hepatocellular carcinoma (HCC).
- HCC management often requires multidisciplinary approaches to optimize patient outcomes.
Purpose of the Study:
- To establish expert recommendations for using 90Y-TARE in converting borderline-resectable HCC to surgical candidacy.
- To synthesize peer-reviewed literature and expert experience regarding 90Y-TARE for HCC downstaging.
Main Methods:
- A multidisciplinary expert working group convened in 2018-2019.
- The group comprised surgical oncologists, liver transplant surgeons, and interventional radiologists.
- Literature review and personal experience with 90Y-TARE were synthesized.
Main Results:
- The document presents expert recommendations based on consensus.
- These recommendations highlight the safety and efficacy of 90Y-TARE.
Conclusions:
- TARE with 90Y is a safe and effective method for converting borderline-resectable HCC patients to surgical candidates.
- Recommendations address potential complications and guide clinical application.
